South Korea's biotechnology company Hyundai Bioscience has completed the development of a niclosamide-based formulation to treat dengue fever with a drug concentration level at or above 50% viral inhibition (IC50), which can also work on Zika, Chikungunya, and Yellow fever viruses.
SEOUL, South Korea, May 3, 2023 /PRNewswire/ -- Hyundai Bioscience (KOSDAQ 048410) announced on the 28th that it had received the clinical study report for the COVID-19 phase 2 clinical trial of its antiviral drug 'Xafty' (code name: CP-COV03).
SEOUL, South Korea , Nov. 25, 2022 /PRNewswire/ -- An innovative anticancer therapy that may complete chemotherapy with two doses of an anticancer drug in as short as 8 days is to enter a clinical trial for cancer patients.
Hyundai Bioscience has announced plans to submit a fast-track processing request for an oral antiviral drug candidate to treat monkeypox, CP-COV03, to the US Food and Drug Administration (FDA).
Hyundai Bioscience has launched the Phase II clinical trial of a new broad-spectrum antiviral agent, CP-COV03, for the treatment of Covid-19 patients.
In a study, oral CP-COV03 plus dexamethasone was found to be 2.1 times effective than dexamethasone alone.